Get started
Author

Eva Budman

Observed institution: Sanofi (United States)
OpenAlex ID: A5058302196
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease
2015 · Karen M. Ashe, Eva Budman, et al. · Molecular Medicine · 105
PDF
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
2016 · John Marshall, Ying Sun, et al. · Molecular Therapy · 102
α-Galactosidase A Knockout Mice
2014 · Dinesh S. Bangari, Karen M. Ashe, et al. · American Journal Of Pathology · 45
PDF
Evaluation of a novel substrate reduction therapy with CNS access in mouse models of neuronopathic Gaucher disease
2015 · John Marshall, Ying Sun, et al. · Molecular Genetics and Metabolism · 1
A novel, selective and orally-available glucosylceramide synthase inhibitor for substrate reduction therapy of Fabry disease
2013 · Karen Ashe, John Marshall, et al. · Molecular Genetics and Metabolism
Works count: 5
Citation count: 253
H-index: 3
I10-index: 3
Year
Topic
Type